Bluejay Diagnostics, Inc. - מכפיל שווי פעילות להכנסות BJDX

Efficient reagent delivery to clinics supports the current trend, where the enterprise value to annual revenue multiple 0.00 indicates the value of this parameter for Bluejay Diagnostics (BJDX). Revenues are based on the sale of the Symphony platform and consumable cartridges. However, the anticipation of FDA approval for sepsis tests and a capital deficit create risks of new share issuances, which impacts the chart.
פילוחי מדדים פיננסיים ומדדי שוק עבור Bluejay (BJDX)

For Bluejay Diagnostics (BJDX), which develops portable rapid blood analysis laboratories, the enterprise value assessment via EV/Sales reflects the market value of the business, accounting for net debt relative to annual revenue. The trend of this indicator allows investors to determine how effectively diagnostic innovations are being capitalized, while a sharp decline in the metric may signal a systemic decrease in the profitability of the operating model.